- Home
- HOTH vs CMMB Comparison
HOTH vs CMMB Comparison
Compare HOTH & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOTH
- CMMB
- Stock Information
- Founded
- HOTH 2017
- CMMB 2004
- Country
- HOTH United States
- CMMB Israel
- Employees
- HOTH N/A
- CMMB N/A
- Industry
- HOTH Biotechnology: Pharmaceutical Preparations
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- HOTH Health Care
- CMMB Health Care
- Exchange
- HOTH Nasdaq
- CMMB Nasdaq
- Market Cap
- HOTH 15.6M
- CMMB 13.7M
- IPO Year
- HOTH 2019
- CMMB N/A
- Fundamental
- Price
- HOTH $1.51
- CMMB $3.09
- Analyst Decision
- HOTH Strong Buy
- CMMB Strong Buy
- Analyst Count
- HOTH 3
- CMMB 2
- Target Price
- HOTH $4.00
- CMMB $26.50
- AVG Volume (30 Days)
- HOTH 1.3M
- CMMB 128.7K
- Earning Date
- HOTH 11-11-2025
- CMMB 11-13-2025
- Dividend Yield
- HOTH N/A
- CMMB N/A
- EPS Growth
- HOTH N/A
- CMMB N/A
- EPS
- HOTH N/A
- CMMB N/A
- Revenue
- HOTH N/A
- CMMB N/A
- Revenue This Year
- HOTH N/A
- CMMB N/A
- Revenue Next Year
- HOTH N/A
- CMMB N/A
- P/E Ratio
- HOTH N/A
- CMMB N/A
- Revenue Growth
- HOTH N/A
- CMMB N/A
- 52 Week Low
- HOTH $0.65
- CMMB $2.39
- 52 Week High
- HOTH $3.80
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- HOTH 44.02
- CMMB 69.21
- Support Level
- HOTH $1.49
- CMMB $2.60
- Resistance Level
- HOTH $1.62
- CMMB $2.79
- Average True Range (ATR)
- HOTH 0.14
- CMMB 0.17
- MACD
- HOTH -0.05
- CMMB -0.02
- Stochastic Oscillator
- HOTH 6.11
- CMMB 72.65
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.